Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3′-Deoxy-3′-[¹⁸F]Fluorothymidine in Preclinical Models of Lung Cancer

Sonja Schelhaas, Annelena Held, Lydia Wachsmuth, Sven Hermann, Davina J. Honess, Kathrin Heinzmann, Donna-Michelle Smith, John R. Griffiths, Cornelius Faber, Andreas H. Jacobs

Cancer Res (2016) 76 (24): 7096–7105.

https://doi.org/10.1158/0008-5472.CAN-16-1479

Published: 15 December 2016

View article titled, Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3′-Deoxy-3′-[<sup>18</sup>F]Fluorothymidine in Preclinical Models of Lung Cancer

Includes: Supplementary data

Journal Articles

Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Gillian M. Tozer, Simon Akerman, Neil A. Cross, Paul R. Barber, Meit A. Björndahl, Olga Greco, Sheila Harris, Sally A. Hill, Davina J. Honess, Christopher R. Ireson, Katie L. Pettyjohn, Vivien E. Prise, Constantino C. Reyes-Aldasoro, Christiana Ruhrberg, David T. Shima, Chryso Kanthou

Cancer Res (2008) 68 (7): 2301–2311.

https://doi.org/10.1158/0008-5472.CAN-07-2011

Published: 01 April 2008

View article titled, Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

Includes: Multimedia, Supplementary data

Journal Articles

The influence of different isoforms of VEGF-A on tumor vascular maturation and response to the vascular disrupting agent, combretastatin A-4 phosphate (CA-4-P)

Gillian M. Tozer, Claudia Coralli, Paul R. Barber, Gabi U. Dachs, Sally A. Hill, Davina J. Honess, Christoper R. Ireson, Chryso Kanthou, Gemma Lewis, Vivien E. Prise, Christiana Ruhrberg, David Shima, Andrew J. Steele

Cancer Res (2005) 65 (9_Supplement): 912–913.

Published: 01 May 2005

View article titled, The influence of different isoforms of VEGF-A on tumor vascular maturation and response to the vascular disrupting agent, combretastatin A-4 phosphate (CA-4-P)

Journal Articles

Pre-clinical development of DMU212, a cytochrome P450 CYP1A1 and CYP1B1-activated prodrug for targeted cancer therapy

Verna M. McErlane, Saraj Ulhaq, Finuala M. Hylands, Davina J. Honess, Michael R. Stratford, Steven A. Everett, Nicola Wilsher, Paul J. Butler, Gerry A. Potter

Cancer Res (2005) 65 (9_Supplement): 930–931.

Published: 01 May 2005

View article titled, Pre-clinical development of DMU212, a cytochrome P450 CYP1A1 and CYP1B1-activated prodrug for targeted cancer therapy

Journal Articles

Combretastatin-A-4-P induced hypertension can be controlled with conventional antihypertensive therapy in a rat model without compromising the reduction in tumor blood flow

Davina J. Honess, Finuala Hylands, David J. Chaplin, Gillian M. Tozer

Cancer Res (2005) 65 (9_Supplement): 704.

Published: 01 May 2005

View article titled, Combretastatin-A-4-P induced hypertension can be controlled with conventional antihypertensive therapy in a rat model without compromising the reduction in tumor blood flow

NARROW

Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3′-Deoxy-3′-[¹⁸F]Fluorothymidine in Preclinical Models of Lung Cancer

Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

The influence of different isoforms of VEGF-A on tumor vascular maturation and response to the vascular disrupting agent, combretastatin A-4 phosphate (CA-4-P)

Pre-clinical development of DMU212, a cytochrome P450 CYP1A1 and CYP1B1-activated prodrug for targeted cancer therapy

Combretastatin-A-4-P induced hypertension can be controlled with conventional antihypertensive therapy in a rat model without compromising the reduction in tumor blood flow

Email alerts

AACR Journals

Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3′-Deoxy-3′-[18F]Fluorothymidine in Preclinical Models of Lung Cancer

Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors

The influence of different isoforms of VEGF-A on tumor vascular maturation and response to the vascular disrupting agent, combretastatin A-4 phosphate (CA-4-P)

Pre-clinical development of DMU212, a cytochrome P450 CYP1A1 and CYP1B1-activated prodrug for targeted cancer therapy

Combretastatin-A-4-P induced hypertension can be controlled with conventional antihypertensive therapy in a rat model without compromising the reduction in tumor blood flow

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3′-Deoxy-3′-[¹⁸F]Fluorothymidine in Preclinical Models of Lung Cancer